Molecular Diagnostics Dominated by Five Companies
|
By LabMedica International staff writers Posted on 17 Feb 2014 |
|
The latest analysis from Kalorama Information (New York City, NY, USA) finds that 5 companies currently dominate the molecular diagnostics market.
According to report, the 5 companies that currently own the majority of the molecular diagnostics (MD) market are Roche, Hologic, Qiagen, Becton Dickinson, and Abbott, and these alone were estimated to have earned 60% of revenues in the 5.5 billion MD market in 2013.
Top-tier companies are said to continue to dominate due to their global reach and multisegment participation. As in vitro diagnostics (IVD) in North America and Europe offer little growth opportunities for the vast number of tests, the top tier has invested in molecular and personalized medicine testing and has reinforced international connections. The report adds that while the names of the dominating players have not changed extensively in recent years, their revenue growth rates have. High growth has shifted to innovators, while leaders are seeing flatter revenues. For example, “Roche holds the number one market position but growth is slowing,” said Shara Rosen, author of the report. “Roche Diagnostics once earned close to double-digit revenue growth in its molecular test business. This has slowed in the last 2 years.”
The report said that IVD veterans Becton Dickinson, Gen-Probe (now part of Hologic), Abbott Diagnostics, and Siemens Healthcare hold their own in a highly competitive environment, while newcomers Meridian Biosciences and GenMark have made gains with user-friendly, infectious disease tests. Meanwhile, Novartis has stepped out of blood screening to concentrate on other business units.
According to the report, IVD tests are being developed constantly and MD is becoming a go-to resource in clinical practice and is currently the faster-growing part of the diagnostics market.
These and additional findings are published in Kalorama’s "Molecular Diagnostics Six Month Update," the latest, extensive market analysis of the IVD segment, with a bias towards the more developed areas (North America and Western Europe). Given the amount of activity in test development and regulatory and reimbursement challenges, Kalorama focused this update on the last half of 2013.
Related Links:
Kalorama Information
Molecular Diagnostics Six Month Update
.jpg)
According to report, the 5 companies that currently own the majority of the molecular diagnostics (MD) market are Roche, Hologic, Qiagen, Becton Dickinson, and Abbott, and these alone were estimated to have earned 60% of revenues in the 5.5 billion MD market in 2013.
Top-tier companies are said to continue to dominate due to their global reach and multisegment participation. As in vitro diagnostics (IVD) in North America and Europe offer little growth opportunities for the vast number of tests, the top tier has invested in molecular and personalized medicine testing and has reinforced international connections. The report adds that while the names of the dominating players have not changed extensively in recent years, their revenue growth rates have. High growth has shifted to innovators, while leaders are seeing flatter revenues. For example, “Roche holds the number one market position but growth is slowing,” said Shara Rosen, author of the report. “Roche Diagnostics once earned close to double-digit revenue growth in its molecular test business. This has slowed in the last 2 years.”
The report said that IVD veterans Becton Dickinson, Gen-Probe (now part of Hologic), Abbott Diagnostics, and Siemens Healthcare hold their own in a highly competitive environment, while newcomers Meridian Biosciences and GenMark have made gains with user-friendly, infectious disease tests. Meanwhile, Novartis has stepped out of blood screening to concentrate on other business units.
According to the report, IVD tests are being developed constantly and MD is becoming a go-to resource in clinical practice and is currently the faster-growing part of the diagnostics market.
These and additional findings are published in Kalorama’s "Molecular Diagnostics Six Month Update," the latest, extensive market analysis of the IVD segment, with a bias towards the more developed areas (North America and Western Europe). Given the amount of activity in test development and regulatory and reimbursement challenges, Kalorama focused this update on the last half of 2013.
Related Links:
Kalorama Information
Molecular Diagnostics Six Month Update
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Multi-Chamber Washer-Disinfector
WD 390
New
Automated Urinalysis Solution
UN-9000
Latest Industry News
- Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
- FDA Clears Blood-Based Companion Diagnostic for Advanced Breast Cancer Therapy
- CareDx Expands Precision Oncology Portfolio with Naveris Acquisition
- Thermo Fisher Scientific to Sell Microbiology Business to Astorg
- Collaboration Expands Access to Rapid Metagenomic Diagnostics for Complex Infections
- Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID
- QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition
- QIAGEN Showcases Integrated Sample-to-Insight Oncology Solutions at AACR 2026
- Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
- Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring
- Beckman Coulter Gains CE Mark for Rapid Assay Distinguishing Bacterial vs Viral Infections
- Junction, GRAIL Enable Scalable Access to Multi-Cancer Detection Test
- GRAIL Partners with Epic to Integrate Multi-Cancer Test into EHR
- Global Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
- Takara Bio USA and Hamilton Partner to Automate NGS Library Preparation
- Lunit and CellCarta Collaborate to Expand AI Pathology in CDx Development
Channels
Clinical Chemistry
view channel
Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of... Read more
Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
High blood pressure during pregnancy is common and can progress to pre-eclampsia, making close monitoring at antenatal visits essential. However, most risk assessment begins only after pregnancy has started.... Read more
Molecular Diagnostics
view channel
Liquid Biopsy Biomarkers Distinguish Inflammatory Breast Cancer and Support Monitoring
Inflammatory breast cancer is among the most aggressive forms of breast malignancy and remains challenging to diagnose and monitor. Obtaining tumor tissue can be difficult, and standard genome and RNA... Read more
Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
Immunotherapy has transformed cancer care, yet durable benefit remains limited to a subset of patients, and clinicians still lack reliable tools to predict response before treatment begins.... Read more
Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
Respiratory infections drive heavy testing volumes in clinical laboratories, where accurate, timely results across multiple pathogens are essential. Many labs are seeking to streamline workflows and increase... Read more
Hematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read more
Immunology
view channel
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more
T-Cell Senescence Profiling May Predict CAR T Responses
Chimeric antigen receptor (CAR) T-cell therapy can deliver striking, durable remissions, yet many patients experience minimal or no benefit. The quality of patient-derived cytotoxic T lymphocytes used... Read more
Microbiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read more
Pathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read more
Technology
view channel
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read more
